Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02949960 · ClinicalTrials.gov registry record · Phase 2
DMT210 Topical Gel in the Treatment of Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Dermata Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT02949960: Completed Phase 2 study of Atopic Dermatitis, sponsored by Dermata Therapeutics.
NCT02949960 is a Phase 2 study of Atopic Dermatitis that has completed, run by Dermata Therapeutics. The registered enrollment target is 19 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02949960, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Dermata Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of the study is to evaluate the safety and efficacy of DMT210 Gel, 5% compared to vehicle control following 28 days of twice-daily topical application to selected target lesions in male and female patients with mild to moderate atopic dermatitis (AD).
Primary Outcome
Change from baseline in ADSI score between Vehicle and 5% gel
Conditions Studied
Interventions
- DRUG DMT210 Topical Gel
- DRUG Vehicle Control
Study Locations (2)
Texas
- Dermata Investigational Site - Houston
Virginia
- Dermata Investigational Site - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-10 |
| Est. Completion | 2017-07-14 |
| Phase | Phase 2 |
What the finished NCT02949960 record still lists
NCT02949960 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which DMT210 Topical Gel is the first listed.
NCT02949960 reports a single indexed study location in Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT02949960 about?
NCT02949960 is a clinical study titled "DMT210 Topical Gel in the Treatment of Atopic Dermatitis". The objective of the study is to evaluate the safety and efficacy of DMT210 Gel, 5% compared to vehicle control following 28 days of twice-daily topical application to selected target lesions in male and female patients with mild to moderate atopic dermatitis (AD).
What is the current status of trial NCT02949960?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2016-10. Estimated completion is 2017-07-14.
What conditions does trial NCT02949960 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT02949960?
The interventions under investigation include: DMT210 Topical Gel (DRUG), Vehicle Control (DRUG).
Who is sponsoring clinical trial NCT02949960?
This trial is sponsored by Dermata Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02949960 being conducted?
This trial has 2 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02949960's enrollment target sits among peer trials
19 140th of 150 higher than 10 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia